<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04071119</url>
  </required_header>
  <id_info>
    <org_study_id>22301</org_study_id>
    <secondary_id>K01AA026874</secondary_id>
    <nct_id>NCT04071119</nct_id>
  </id_info>
  <brief_title>Alcohol and Cigarette Craving During Oxytocin Treatment</brief_title>
  <official_title>The Neural Mechanisms Associated With Alcohol and Cigarette Craving in Alcohol Use Disorder Smokers During Oxytocin Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposed research seeks to examine the behavioral and neural substrates of intranasal
      oxytocin compared to placebo on alcohol cue-induced alcohol and cigarette craving smokers
      with an alcohol use disorder (AUD). Non treatment-seeking smokers with an AUD will be
      recruited to participate in a between-subjects, placebo-controlled, randomized pilot
      functional magnetic resonance imaging (fMRI) study. Participants will undergo an fMRI scan in
      conjunction with an alcohol-olfactory cue-reactivity task. Secondary assessments will include
      alcohol and cigarette craving, alcohol and cigarette consumption, physiological measures
      (heart rate and blood pressure) and mood measures.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol craving</measure>
    <time_frame>1 day</time_frame>
    <description>average alcohol craving during the cue-reactivity task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cigarette craving</measure>
    <time_frame>1 day</time_frame>
    <description>average cigarette craving during the cue-reactivity task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain activity</measure>
    <time_frame>1 day</time_frame>
    <description>BOLD response when comparing alcohol to neutral cues during fMRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol and cigarette consumption</measure>
    <time_frame>5-7 days</time_frame>
    <description>alcohol and cigarette consumption assessed by the Timeline Followback</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Oxytocin nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>Participants administer the oxytocin (40 IU) twice a day for 5 - 7 days</description>
    <arm_group_label>Oxytocin nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants administer the placebo (40 IU) twice a day for 5 - 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male or female

          2. 18 to 55 years of age

          3. meet criteria for Alcohol Use Disorder DSM-5 diagnosis

          4. meet the National Institute on Alcohol Abuse and Alcoholism criteria for
             heavy-drinking

          5. smoke at least ≥5 cigarettes/day for at least a year, verified with breath carbon
             monoxide level &gt; 5 ppm

          6. in good health as confirmed by medical history, physical examination and lab tests

          7. willing to take the medication and adhere to the study procedures

          8. breath alcohol concentration (BrAC) = 0.00 at each visit

          9. understand informed consent and questionnaires written in English at an 8th grade
             level

         10. right-handedness

         11. normal to normal-corrected vision

        Exclusion Criteria:

          1. positive urine test for pregnancy

          2. women who are breast-feeding

          3. body mass index &gt; 40

          4. current or prior history of any clinically significant disease, cardiovascular,
             respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders,
             positive hepatitis or HIV test that could affect study participation, as determined by
             the study physician

          5. history of suicide attempts

          6. current diagnosis of substance dependence other than alcohol, nicotine or cannabis as
             assessed by self-report and urine toxicology screen at baseline

          7. current use of psychoactive medications or any medication that may interact with
             oxytocin

          8. history of hypersensitivity to oxytocin

          9. chronic rhinitis or sinusitis

         10. clinically significant electrolyte abnormalities

         11. vasoconstricting medications or prostaglandins

         12. clinically significant medical abnormalities: unstable hypertension, bilirubin &gt;150%
             of the upper normal limit (UNL), ALT/AST &gt;500% the UNL, creatinine clearance ≤60
             dl/min)

         13. significant alcohol withdrawal symptoms, defined as a CIWA-Ar &gt; 8

         14. positive urine drug screen at baseline for any excluded substances

         15. individuals seeking treatment

         16. meets DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other
             psychoses

         17. claustrophobia

         18. any contraindications with the MRI machine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kimberly Goodyear, Ph.D.</last_name>
    <phone>401-863-6626</phone>
    <email>kimberly_goodyear@brown.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Alcohol and Addiction Studies</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kimberly Goodyear, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Carolina L Haass-Koffler, Pharm.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert M Swift, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Kimberly Goodyear</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>craving</keyword>
  <keyword>alcohol use disorder</keyword>
  <keyword>smoking</keyword>
  <keyword>cigarettes</keyword>
  <keyword>drinking</keyword>
  <keyword>functional magnetic resonance imaging</keyword>
  <keyword>cue-reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

